Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study will estimate the absolute bioavailability of subcutaneously injected GS-5745,
characterize the safety, tolerability, and pharmacokinetics (PK) of GS-5745 after
subcutaneous (SC) injection and intravenous (IV) administration, and evaluate the formation
of anti-GS-5745 antibodies after SC and IV administration.